Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer

Who could benefit from this research

What this research studies

This project looks at how prostate cancer tumors change their identity to evade treatment and become more dangerous. Researchers will study markers and genomic features linked to lineage plasticity, such as TP53/RB1 changes and EZH2/SOX2 activity, to better define which tumors behave aggressively. The work may involve analyzing tumor samples, biomarker patterns, and responses to potential targeted strategies to prevent or overcome resistance. The goal is to pave the way for more effective therapies for men with metastatic, treatment-resistant prostate cancer.

Why it matters

Where this research is happening

• Sloan-Kettering Inst Can Research
  New York, United States Active

Researchers

• Principal investigator: Sawyers, Charles L. — Sloan-Kettering Inst Can Research
• Study coordinator: Sawyers, Charles L.

Related research

Other NIH-funded projects on the same topics.

• Understanding how aggressive cell states emerge in castration-resistant prostate cancer

  A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11463275

• Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer

  Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.

  NIH research University of Maryland Baltimore · Baltimore, United States · NIH-11452128

• Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer

  Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11427360

• Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy

  This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11419184

• Hyperactive methylation in a hard-to-treat prostate cancer subtype

  Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415138

• Stopping therapy-resistant prostate cancer by blocking FOXA2 and AP-1

  This research looks at whether blocking a protein switch called FOXA2 and its partner AP‑1 can stop or reverse prostate cancers that no longer respond to hormone therapy.

  NIH research University of Massachusetts Boston · Boston, United States · NIH-11404787

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.